Case report: Impact of BITE on CAR‐T cell expansion. Issue 3 (15th February 2019)

• Record Type: Journal Article
• Authors: Shalabi, Haneen; Koegel, Ashley; Ponduri, Anusha; Qin, Haiying; Salem, Dalia; Stetler‐Stevenson, Maryalice; Yuan, Constance; Yates, Bonnie; Delbrook, Cindy; Loh, Mignon; Fry, Terry J.; Shah, Nirali N.
• Is Part Of: Advances in cell and gene therapy. Volume 2:Issue 3(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-02-15
• Subjects: chimeric antigen receptor T cell -- immunotherapy -- leukemia; Cellular therapy -- Periodicals; Gene therapy -- Periodicals; Immunotherapy -- Periodicals; Cancer -- Treatment -- Periodicals; Bone marrow -- Diseases -- Treatment -- Periodicals; Blood -- Diseases -- Treatment -- Periodicals; 615.5
• DOI: 10.1002/acg2.50
• Languages: English
• ISSNs: 2573-8461

Abstract

Abstract: Targeted immunotherapeutic approaches have become an attractive, novel therapy in the treatment of chemotherapy resistant or relapsed high‐risk acute lymphoblastic leukemia (ALL). Many of these therapies, chimeric antigen receptor (CAR) T cells, and bispecific T‐cell engagers (BiTE) in particular, rely on surface expression of the antigen for activity and efficacy. As such, antigen loss is a growing problem in this relapsed population. We present a case of relapsed, refractory B‐ALL that has immunophenotypic variability in the leukemia blasts in response to the sequential targeted immunotherapies received. This case additionally describes a bolstered CAR‐T cell expansion after the patient received subsequent blinatumomab therapy, suggesting a potential strategy for utilization of multiagent immunotherapies to have synergistic approaches to eradicate disease and prolong remission in patients with relapsed hematologic malignancies (Anti‐CD22 chimeric receptor T cells in pediatric and young adult patients with recurrent or relapsed CD22‐expressing B‐cell malignancies. clinicaltrials.gov NCT02315612).